News | July 21, 2022
Syngene reports revenue from operations up 8% in Q1 FY 23
Company raises the annual revenue guidance from mid-teens to high teens
Company raises the annual revenue guidance from mid-teens to high teens
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Bringing next-gen cannabinoid therapeutics to cancer patients
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
The new facility at Dombivli is the fifth ASG Eye Hospital in Maharashtra
Subscribe To Our Newsletter & Stay Updated
